JPWO2020160441A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020160441A5 JPWO2020160441A5 JP2021544728A JP2021544728A JPWO2020160441A5 JP WO2020160441 A5 JPWO2020160441 A5 JP WO2020160441A5 JP 2021544728 A JP2021544728 A JP 2021544728A JP 2021544728 A JP2021544728 A JP 2021544728A JP WO2020160441 A5 JPWO2020160441 A5 JP WO2020160441A5
- Authority
- JP
- Japan
- Prior art keywords
- trem2
- optionally
- cells
- acid sequence
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700019146 Transgenes Proteins 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 69
- 210000004027 cell Anatomy 0.000 claims description 67
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 47
- 208000027626 Neurocognitive disease Diseases 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 10
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 10
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 10
- 230000001149 cognitive effect Effects 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 210000000274 microglia Anatomy 0.000 claims description 7
- 210000001616 monocyte Anatomy 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 208000021320 Nasu-Hakola disease Diseases 0.000 claims description 6
- 230000002025 microglial effect Effects 0.000 claims description 6
- 208000031334 polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly Diseases 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 4
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 4
- 208000036546 leukodystrophy Diseases 0.000 claims description 4
- 230000003340 mental effect Effects 0.000 claims description 4
- 210000003643 myeloid progenitor cell Anatomy 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 210000003995 blood forming stem cell Anatomy 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 210000002304 esc Anatomy 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 238000010322 bone marrow transplantation Methods 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000019771 cognition Effects 0.000 claims description 2
- 230000006999 cognitive decline Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 238000012502 risk assessment Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 description 66
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 description 66
- 150000007523 nucleic acids Chemical group 0.000 description 45
- 108091028043 Nucleic acid sequence Proteins 0.000 description 44
- 108091033319 polynucleotide Proteins 0.000 description 42
- 102000040430 polynucleotide Human genes 0.000 description 42
- 239000002157 polynucleotide Substances 0.000 description 42
- 239000013603 viral vector Substances 0.000 description 9
- 241000712907 Retroviridae Species 0.000 description 5
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 108091028066 Mir-126 Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000023881 membrane protein ectodomain proteolysis Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- NODCQQSEMCESEC-UHFFFAOYSA-N 5-(1h-pyrrolo[2,3-b]pyridin-3-ylmethyl)-n-[[4-(trifluoromethyl)phenyl]methyl]pyridin-2-amine Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=CC=C12 NODCQQSEMCESEC-UHFFFAOYSA-N 0.000 description 1
- NSMOZFXKTHCPTQ-UHFFFAOYSA-N 6-fluoro-n-[(5-fluoro-2-methoxypyridin-3-yl)methyl]-5-[(5-methyl-1h-pyrrolo[2,3-b]pyridin-3-yl)methyl]pyridin-2-amine Chemical compound COC1=NC=C(F)C=C1CNC(N=C1F)=CC=C1CC1=CNC2=NC=C(C)C=C12 NSMOZFXKTHCPTQ-UHFFFAOYSA-N 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 102000035485 Allograft inflammatory factor 1 Human genes 0.000 description 1
- 108091010877 Allograft inflammatory factor 1 Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000011597 CGF1 Diseases 0.000 description 1
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 description 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 description 1
- 108700004991 Cas12a Proteins 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101000746022 Homo sapiens CX3C chemokine receptor 1 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 102100026171 P2Y purinoceptor 12 Human genes 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 108010014270 Purinergic P2Y12 Receptors Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100037029 Transmembrane protein 119 Human genes 0.000 description 1
- 101710170979 Transmembrane protein 119 Proteins 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- JGWRKYUXBBNENE-UHFFFAOYSA-N pexidartinib Chemical compound C1=NC(C(F)(F)F)=CC=C1CNC(N=C1)=CC=C1CC1=CNC2=NC=C(Cl)C=C12 JGWRKYUXBBNENE-UHFFFAOYSA-N 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036362 sensorimotor function Effects 0.000 description 1
- 230000004039 social cognition Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024210953A JP2025032191A (ja) | 2019-02-01 | 2024-12-04 | 神経認知障害を処置するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800056P | 2019-02-01 | 2019-02-01 | |
| US62/800,056 | 2019-02-01 | ||
| PCT/US2020/016163 WO2020160441A1 (en) | 2019-02-01 | 2020-01-31 | Compositions and methods for treating neurocognitive disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024210953A Division JP2025032191A (ja) | 2019-02-01 | 2024-12-04 | 神経認知障害を処置するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523123A JP2022523123A (ja) | 2022-04-21 |
| JPWO2020160441A5 true JPWO2020160441A5 (enrdf_load_stackoverflow) | 2023-04-25 |
Family
ID=71841290
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544728A Pending JP2022523123A (ja) | 2019-02-01 | 2020-01-31 | 神経認知障害を処置するための組成物及び方法 |
| JP2024210953A Pending JP2025032191A (ja) | 2019-02-01 | 2024-12-04 | 神経認知障害を処置するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024210953A Pending JP2025032191A (ja) | 2019-02-01 | 2024-12-04 | 神経認知障害を処置するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220133850A1 (enrdf_load_stackoverflow) |
| EP (1) | EP3917623A4 (enrdf_load_stackoverflow) |
| JP (2) | JP2022523123A (enrdf_load_stackoverflow) |
| CA (1) | CA3127804A1 (enrdf_load_stackoverflow) |
| IL (1) | IL285268A (enrdf_load_stackoverflow) |
| MA (1) | MA54873A (enrdf_load_stackoverflow) |
| WO (1) | WO2020160441A1 (enrdf_load_stackoverflow) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| WO2022006105A2 (en) * | 2020-07-02 | 2022-01-06 | Avrobio, Inc. | Compositions and methods for treating neurocognitive disorders |
| EP4504224A1 (en) * | 2022-04-07 | 2025-02-12 | The Regents of the University of California | Methods for treating alzheimer's disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050163760A1 (en) * | 2001-12-06 | 2005-07-28 | Nathalie Cartier-Lacave | Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| WO2014074942A1 (en) * | 2012-11-08 | 2014-05-15 | Illumina, Inc. | Risk variants of alzheimer's disease |
| US11066456B2 (en) * | 2016-02-25 | 2021-07-20 | Washington University | Compositions comprising TREM2 and methods of use thereof |
| JP2019531332A (ja) * | 2016-07-22 | 2019-10-31 | ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー．ファウ．（デーツェットエンエー） | Ｔｒｅｍ２切断モジュレーター及びその使用 |
| KR20200032722A (ko) * | 2017-07-27 | 2020-03-26 | 노파르티스 아게 | 부분절단효소 내성 trem2 변이체 |
-
2020
- 2020-01-31 CA CA3127804A patent/CA3127804A1/en active Pending
- 2020-01-31 WO PCT/US2020/016163 patent/WO2020160441A1/en unknown
- 2020-01-31 MA MA054873A patent/MA54873A/fr unknown
- 2020-01-31 US US17/427,429 patent/US20220133850A1/en active Pending
- 2020-01-31 JP JP2021544728A patent/JP2022523123A/ja active Pending
- 2020-01-31 EP EP20748276.1A patent/EP3917623A4/en active Pending
-
2021
- 2021-08-01 IL IL285268A patent/IL285268A/en unknown
-
2024
- 2024-12-04 JP JP2024210953A patent/JP2025032191A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11965174B2 (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
| JP2022508182A (ja) | 組換えウイルスベクター及びそれの産生のための核酸 | |
| US20140341852A1 (en) | Capsid-modified raav vector compositions and methods therefor | |
| US8278428B2 (en) | Mitochondrial nucleic acid delivery systems | |
| JP2018520646A (ja) | ファブリー病の遺伝子治療 | |
| BR112013023185B1 (pt) | Molécula de ácido nucléico linear isolada, método para produzir uma molécula de ácido nucléico linear isolada, método in vitro para mediar a expressão do dna exógeno em uma célula de mamífero e método in vitro para efetuar a expressão do produto de gene dessejado ou oligonucleotídeo em uma célula | |
| Flotte et al. | Viral vector–mediated and cell-based therapies for treatment of cystic fibrosis | |
| US20250136994A1 (en) | Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome | |
| JP7616668B2 (ja) | Ｕｂｅ３ａ遺伝子および発現カセットならびにそれらの使用 | |
| JPWO2020160458A5 (enrdf_load_stackoverflow) | ||
| Hoshino et al. | The adeno-associated virus rh10 vector is an effective gene transfer system for chronic spinal cord injury | |
| Minskaia et al. | Viral vectors in gene replacement therapy | |
| US12358954B2 (en) | Capsid-modified rAAV vector compositions and methods therefor | |
| JPWO2020160468A5 (enrdf_load_stackoverflow) | ||
| WO2022015856A1 (en) | Compositions and methods for treating an inherited retinal disease | |
| JPWO2020160441A5 (enrdf_load_stackoverflow) | ||
| US20250171778A1 (en) | Treatments of Disorders of Myelin | |
| JPWO2019173756A5 (enrdf_load_stackoverflow) | ||
| US20240067942A1 (en) | Lysosomal acid lipase variants and uses thereof | |
| Silver et al. | Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies | |
| EP4355879A2 (en) | Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins | |
| JP2024542015A (ja) | 脳内でのｔｃｆ７ｌ２媒介性髄鞘再生 | |
| Kojima et al. | The adeno-associated virus rh10 vector is an effective gene transfer system for chronic spinal cord injury | |
| Seymour et al. | European Society of Gene and Cell Therapy British Society for Gene Therapy Collaborative Congress 2011 October 27–31, 2011 The Brighton Centre, Brighton United Kingdom | |
| Gøtzsche et al. | GENE THERAPY IN THE CNS–PROGRESS AND PROSPECTS FOR NOVEL THERAPIES |